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Background: Little information exists on the prevalence and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in
patients admitted for acute exacerbations of chronic obstructive pulmonary disease (COPD). Objective: To review available literature, we
performed a Medline search on papers published on this topic between 1966 and 2003. Data synthesis: Pulmonary emboli have been
frequently found (up to 30% of cases) in autoptic series that included patients who died from acute exacerbation of COPD, while the real
incidence of PE during exacerbation has never been prospectively evaluated by large-scale clinical studies. Diagnosis of concomitant PE in
these patients is often missed because symptoms of acute exacerbation of COPD may mimic PE, and non-invasive evaluation by pulmonary
scintigraphy or CT scan is less specific. Even if not fatal, undetected and untreated PE may lead to long-term morbidity from pulmonary
hypertension and predispose to recurrent venous thromboembolism (VTE). DVT of the lower extremities affects about 10% of patients with
acute exacerbation of COPD at admission, but the rate is likely to be underestimated. The results of clinical trials conducted on general
medical patients, including COPD patients, indicate that unfractionated heparin (UH) and low molecular weight heparin (LMWH)
significantly reduce VTE rates. However, subgroup data on COPD patients are generally not available. In a single randomised, controlled
trial specifically conducted on COPD patients, nadroparin reduced the rate of DVT from 28% to 15% without affecting mortality.
Conclusions: Despite a substantial lack of consistent data, VTE appears as a major threat to patients admitted for acute exacerbation of
COPD, and pharmacologic prophylaxis should be considered in all high risk situations. However, methodologically rigorous studies in this
setting are still needed.
D 2004 Elsevier Ltd. All rights reserved.Keywords: Deep vein thrombosis, pulmonary embolism; COPD, prevalence, prevention
1. Introduction medical patients than in surgical patients: it was calculatedVenous thromboembolism (VTE) is a common disorder
that includes deep vein thrombosis (DVT) and pulmonary
embolism (PE). PE most commonly results from DVT of the
lower limbs and represents a major cause of morbidity and
mortality. Clinical risk factors for VTE include increasing
age, prolonged immobility, previous VTE, cancer, surgery,
trauma, estrogen use, and congenital and acquired thrombo-
philic disorders. The prevalence of VTE and the efficacy of
thromboprophylaxis have been less extensively evaluated in0049-3848/$ - see front matter D 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.thromres.2003.12.003
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E-mail address: mambrosetti@fsm.it (M. Ambrosetti).that nearly 100,000 patients have been enrolled in trials
evaluating VTE in surgery whereas approximately only
15,000 patients were included in trials evaluating medical
patients [1].
Among medical conditions, patients with myocardial
infarction and ischaemic stroke are those with the highest
risk of VTE. The overall incidence of DVT is approximately
24% among patients with myocardial infarction, and
increases to more than 50% after ischemic stroke [2].
Patients who are admitted for acute exacerbations of
chronic obstructive pulmonary disease (COPD) are gener-
ally considered to be at moderate risk for the development
of VTE because of the presence of concomitant risk factors
such as immobilization, bronchial superinfection, right ven-
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death occurs in approximately 8% of patients admitted for
an acute exacerbation of COPD, and the rate of mortality
increases following hospital discharge to up to 23% after 1
year. However, little attention has been given to VTE as a
cause of morbidity and mortality in this patient setting. To
evaluate all available information on the prevalence and
prevention of VTE in patients hospitalized for acute exac-
erbations of COPD, and to possibly generate evidence based
recommendations, a systematic search of the literature was
carried out.2. Literature search and data sources
We performed a series of MEDLINE database searches
for English language literature published from 1966 to
November 2003 using the following Medical Subject Head-
ings’ terms: deep vein thrombosis, pulmonary embolism,
venous thromboembolism, chronic obstructive pulmonary
disease, chronic bronchitis, and heparin. We also supple-
mented references by cross checking bibliographies of
retrieved articles to identify additional studies.
The prevalence of VTE in patients with COPD was
evaluated by reviewing autoptic studies and prospective
observational studies, while the efficacy of prophylaxis
was estimated by evaluating randomised controlled trials.
Criteria for the inclusion of trials on prophylaxis in medical
patients were those defined by the Sixth Consensus Con-
ference on Antithrombotic Therapy of the American College
of Chest Physicians (randomized design, sample size not
< 10 patients per group, contrast venography or fibrinogen
leg scanning as diagnostic tool and adoption of currently
approved drugs) [2]. This strategy produced a total of 20
articles, 8 on the prevalence of VTE [4,5,10–12,14–16] and
12 on VTE prophylaxis [9,17–27]. Because a formal
combined statistical analysis of these studies was not
appropriate due to the heterogeneity of methodology, a
simple qualitative overview of available data was carried
out.3. Prevalence of VTE in COPD
PE is a relatively frequent cause of death in patients with
COPD. In a multicenter European study conducted on 215
stable COPD patients treated with long-term oxygen therapy
(LTOT) [4], PE accounted for 10% of all deaths. The
frequency of fatal PE during acute exacerbation of COPD
appears to be even higher when evaluated by autoptic
studies. Neuhaus et al. [5] found pulmonary emboli in
27% of 66 autopsies performed in patients who had respi-
ratory failure (not only as a decompensation of COPD) and
died after admission to a Respiratory Intensive Care Unit. It
is remarkable to observe that in this patient population PE
was clinically suspected only in half of the cases and that nospecific symptoms were described, thus supporting the
concept that clinical suspicion of PE in stable [6,7] and
acute exacerbation of COPD is particularly difficult, for
clinical symptoms of COPD may mimic PE symptoms.
Moreover, the intrinsic limitations of the ventilation/perfu-
sion scintigraphy may also contribute to the underestimation
of the prevalence of VTE in COPD patients [8].
The frequency of PE during acute exacerbation of COPD
has never been evaluated by methodologically rigorous
prospective large-scale studies. The prevalence of this
condition ranged from 0% [9] to 29% [10] in small series
that were limited either by the absence of scintigraphic
confirmation or by selection bias.
Several clinical studies have evaluated the prevalence of
DVT in patients admitted for an episode of exacerbation of
COPD [11,12,14–16]. However, the value of their results is
weakened by the sample size and by the diagnostic techni-
ques that were adopted.
Prescott et al. [11] performed contrast venography and
125I-Fibrinogen scans within 7 days after admission in a
group of 45 bedridden patients, and showed a 9% overall
incidence of DVT in the absence of pharmacologic and
mechanical prophylaxis. In a study by Winter et al. [12], a
group of 29 patients underwent autologous platelet labelling
with indium-111 4 to 13 days after hospital admission. A
DVT rate of 45% was observed.
When ultrasonography was used as a diagnostic tool, the
prevalence of DVTwas reported between 0% [14] in a small
study on 33 males and 10% in two larger studies [15,16].
Ultrasonography (US) is safe, noninvasive, and relatively
inexpensive, but it is limited by operator dependency and it
is inadequately sensitive and specific both in asymptomatic
patients and in the detection of calf vein DVT [13].
The largest study was conducted by Schonhofer and
Kohler [15] on a population of 196 patients admitted to a
respiratory intensive care unit. The authors found a DVT
rate of 10.7% as assessed by US. The majority (86%) of
cases were asymptomatic and, interestingly, almost all major
clinical variables (such as age, weight, severity of dyspnea,
lung function, situation of blood gases) failed to predict
patients who were more likely to develop DVT. The
importance of these results is highlighted by two consid-
erations. First, this observational study excluded COPD
patients also suffering from cancer, cardiac failure, or with
a history of previous VTE, thus showing the relatively high
frequency of DVT in patients without concomitant major
risk factors. Second, the reported DVT rate was likely to be
underestimated because of the limitations of US and be-
cause calf veins were not explored.4. Prevention of VTE in COPD
To our knowledge, there is only one randomised con-
trolled trial specifically conducted in patients with COPD.
The Association of Non-University Affiliated Intensive
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molecular weight heparin (LMWH) nadroparin with placebo
in patients with acute decompensated COPD who required
mechanical ventilation in 34 intensive care units. In the
group of 85 patients randomized to placebo, the observed
rate of venographically detected DVT was 28%, with a rate
of proximal and isolated calf DVT of 8% and 20%,Table 1
Summary of major published studies of VTE in COPD patients according to ado
First author,
year (ref no.)
Study population Patients with DVT
by 125I fibrinogen
scanning
Patients with
DVT by US
Doc
DV
clin
app
All
COPD
Medical
patients,
COPD
included
All
DVT
Proximal
DVT
Dahan, 1986
[18]
131 12 (9.1%) ? ? ?
Dahan, 1986
[18]
132 4 (3%) ? ? ?
Bergmann, 1996
[19]
1230a
Bergmann, 1996
[19]
1244a
Samama, 1999
[17]
288 ? ? ? 2
(0.7
Samama, 1999
[17]
287 ? ? ? 3
(1%
Samama, 1999
[17]
291 ? ? ? 1
(0.3
Gardlund, 1996
[21]
5776 ? ? ? ?
Gardlund, 1996
[20]
5917 ? ? ? ?
Lechler, 1996
[21]
477
Lechler, 1996
[21]
482
Harenberg, 1996
[22]
810 3
(0.4%)c
Harenberg, 1996
[23]
780 1
(0.1%)c
Fraisse, 2000
[9]
109**
Fraisse, 2000
[9]
114**
COPD= chronic obstructive pulmonary disease; DVT= deep vein thrombosis;
compression stocking; LMWH= low molecular weight heparin; UFH= unfraction
*Detection of DVT by venography and ultrasonography in 83% and 17% of all
**All patients with acute decompensated COPD requiring mechanical ventilation
a Acute pulmonary disease accounted for 22% of the total patients population
b Necropsy-verified PE.
c Distal veins not examined; phlebography only performed in patients with ne
d One death in the nadroparine group suspected for PE (neither angiography
e 0.4 ml daily for 45 to 70 kg; 0.6 ml for 71 to 110.respectively. In the group of 84 patients randomized to
receive nadroparin until they could be weaned from me-
chanical ventilation, the occurrence of DVTwas significant-
ly reduced to 15.6% (proximal and distal DVT 3.6% and
12%, respectively). Since PE was not systematically inves-
tigated by objective tests, it is difficult to extrapolate data on
the efficacy of LMHW prophylaxis in preventing PE inpted thromboprophylaxis
umented
T and
ically
arent
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venographically
confirmed DVT
Patients
with PE
Patients
with fatal
PE
Prophylaxis
regimen
All
DVT
Proximal
DVT
? ? ? 3
(2.3%)
EA
? ? ? 1
(0.8%)
EA, LMWH
(Pharmuka 10169
60 mg daily)
10 (0.8%) LMWH
(Nadroparin 0.3 ml
once daily)
17
(1.4%)
Placebo
%)
41
(14.2%)*
14
(4.9%)*
3
(1%)
0
(0%)
ES
)
43
(14.9%)*
13
(4.5%)*
1
(0.3%)
0
(0%)
ES, LMWH
(Enoxaparin 20 mg)
%)
16
(5.5%)*
5
(1.7%)*
0
(0%)
0
(0%)
ES, LMWH
(Enoxaparin 40 mg)
? ? ? 15
(8%)b
UFH
(5000 IU bid)
? ? ? 16
(8%)b
None
1
(0.2%)
0 0 LMWH
(Enoxaparin 40 mg)
4
(0.9%)
2
(0.5%)
UFH
(Calciparine 5000
IU tid)
3
(0.4%)
LMWH
(Nadroparin 36 mg)
3
(0.4%)
UFH
(Calciparine 5000
IU tid)
13/84
(15.5%)
3/84
(3.6%)
0 0d LMWH
(Nadroparin based
on patients’ body
weight)e
24/85
(28.2%)
7/85
(8.2%)
0 0 Placebo
US= ultrasound; PE = pulmonary embolism; ASA= aspirin; GCS= graded
ated heparin; EA= early ambulation.
patients, respectively.
.
s (treated plus placebo groups, n= 2474).
gative or uncertain US results and clinical suspicion of DVT.
nor autopsy performed).
Table 2
Safety of heparin prophylaxis in patients with COPD
First author, Study population Adverse events in the study period Prophylaxis regimen
year (ref no.)
All
COPD
Medical patients,
COPD included
Minor
bleeding
Major
bleeding
Fatal
bleeding
Local
hematoma
Thrombocytopenia Severe
thrombocytopenia
Samama, 1999 [17] 362 27
(7.5%)
4
(1.1%)
0 0 13
(3.6%)
3
(0.8%)a
ESb
Samama, 1999 [17] 351 40
(11.4%)
1
(0.3%)
0 4
(1.1%)c
10
(2.8%)
0 ES, LMWH
(Enoxaparin 20 mg)b
Samama, 1999 [17] 360 39
(10.8%)
6
(1.7%)
1
(0.3%)
5
(1.4%)c
8
(2.2%)
0 ES, LMWH
(Enoxaparin 40 mg)b
Lechler, 1996 [21] 477 13
(2.7%)
2
(0.4%)
0 22
(4.6%)c
0 LMWH
(Enoxaparin 40 mg)
Lechler, 1996 [21] 482 6
(1.2%)
9
(1.9%)
2
(0.4%)
52
(10.8%)c
0 UFH
(Calciparine 5000 IU tid)
Harenberg, 1996 [22] 810 3
(0.4%)
5
(0.6%)
0 0 LMWH
(Nadroparin 36 mg)
Harenberg, 1996 [23] 780 7
(0.9%)
4
(0.5%)
0 4d
(0.5%)
UFH
Calciparine 5000 IU tid)
Fraisse, 2000 [9] 108 19
(17.6%)
6
(5.6%)
0 10e
(9.3%)
3
(2.8%)
LMWH
(Nadroparin based on
patients’ body weight)
Fraisse, 2000 [9] 113 15
(13.3%)
3
(2.7%)
0 7e
(6.2%)
2
(1.8%)
Placebo
a Platelet count of less than 50,000 per cubic millimeter.
b Treatment period 14 days.
c > 5 cm in diameter.
d Platelet count ranged 40,000 to 80,000 per cubic millimeter.
e Platelet count of less than 100,000 per cubic millimeter.
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ity, although most deaths were due to cardiovascular com-
plications or nosocomial infections, reflecting the serious
conditions of these patients. The incidence of major bleed-
ing and thrombocytopenia related to active treatment were
not significantly different between the two groups, with an
incidence of 5% and 1%, respectively, in the LMWH group
and of 2.6% and 1%, respectively, in the placebo group.
COPD patients were also included in a number of clinical
trials designed to assess the efficacy and safety of pharma-
cological prophylaxis in general medical patients (Tables 1
and 2). Unfortunately, these trials did not perform a critical
evaluation of patients with COPD. The largest and most
rigorous study performed in the medical setting was the
Medenox trial [17]. Two dosages of the LMWH enoxaparin,
20 and 40 mg, were compared to placebo in 1102 bedridden
medical patients and were administered for 6 to 14 days.
Patients with acute respiratory failure, with the exclusion of
those requiring ventilatory support, were more than 50% of
all study patients and resulted the largest group included.
The occurrence of deep vein thrombosis was systematically
evaluated with venography at the end of the treatment. After
14 days, there was a statistically significant reduction in
terms of venous thromboembolic events in the group treated
with enoxaparin 40 mg as compared to placebo, but not in
the group treated with enoxaparin 20 mg. Major bleeding
rates and mortality rates were comparable among the three
groups. Unfortunately, no efficacy and safety data can be
extrapolated for the subgroup of patients admitted becauseof respiratory failure. The results of a meta-analysis evalu-
ating for the first time all clinical trials conducted in medical
patients [1] have shown that the risk of deep vein throm-
bosis in internal medicine is similar to the risk of DVT in
general surgery. The meta-analysis also demonstrated that
the use of pharmacologic prophylaxis, either unfractionated
heparin (UFH) or LMWH, reduces the risk of deep vein
thrombosis by 56% and the risk of clinical and fatal
pulmonary embolism by 52%. When compared, UFH and
LMWH showed a similar efficacy, but this latter offered a
52% reduction in the risk of major bleeding events.5. Final comment
VTE is a frequent and serious complication in patients
hospitalized for acute exacerbations of COPD. As in other
medical conditions, there is increasing evidence to support
that pharmacological thromboprophylaxis has an important
role in the in-hospital management of these patients. How-
ever, at the moment specific evidence only exists for
patients admitted to intensive care units for acute decom-
pensated COPD requiring mechanical ventilation. Although
this evidence is only based on the results of a single study, it
is likely that these patients should be considered at moderate
to high risk and to conclude that they should receive daily
prophylactic LMWH. Indeed, further data are needed to
better define the thrombotic risk and to evaluate the efficacy
of pharmacological prophylaxis in reducing the risk of PE in
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patients with acute exacerbation of COPD who do not
require mechanical ventilation, although extrapolation from
trials conducted on general medical patients strongly sup-
port the need for LMWH or UFH. The GOLD guidelines
[28] suggest to adopt LMWH in immobilized, polycythe-
mic, or dehydrated patients with or without a history of
thromboembolic disease. In our opinion, since there is no
strong evidence to support this approach based on the
selection of patients at greatest risk for VTE, the implemen-
tation of prophylaxis for every patient admitted with acute
exacerbation of COPD is likely to be more efficacious.
Thus, since many hospitals are currently developing a
formal strategy that addresses the prevention of VTE in
high-risk groups, it should be warranted that also patients
with acute exacerbation of COPD are included in such a
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